Study in Patients With COPD

This study has been completed.
Sponsor:
Information provided by:
Dey
ClinicalTrials.gov Identifier:
NCT00215384
First received: September 13, 2005
Last updated: November 10, 2010
Last verified: February 2008

September 13, 2005
November 10, 2010
Not Provided
April 2003   (final data collection date for primary outcome measure)
The primary outcome variable is the measure of lung function.
Same as current
Complete list of historical versions of study NCT00215384 on ClinicalTrials.gov Archive Site
Change in lung function will be examined as a secondary outcome, as well as vital signs, physical examination, adverse even reporting, etc.
Same as current
Not Provided
Not Provided
 
Study in Patients With COPD
Not Provided

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
COPD
Drug: Formoterol Fumarate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
35
October 2005
April 2003   (final data collection date for primary outcome measure)

Inclusion Criteria:

-History of COPD and cigarette smoking

Exclusion Criteria:

  • Clinical diagnosis of asthma.
  • Chest X-ray that is diagnostic of a significant pulmonary disease other than COPD
  • Disease of other major organ systems
Both
50 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00215384
DL-052
Not Provided
Director, Clinical Affairs, Dey
Dey
Not Provided
Not Provided
Dey
February 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP